By 2040, alcohol-associated and metabolic dysfunction–related liver disease will be the leading cause of hepatocellular ...

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy ...

It uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line treatments have ...

James J. Harding, MD, provides a high-level overview of systemic therapy for untreated unresectable hepatocellular carcinoma ...

The Barbara Ann Karmanos Cancer Institute, the largest provider of cancer care and research in Michigan and part of McLaren ...

Liver cancer rates have more than tripled in the U.S. since 1980 and continue to rise. More than 41,000 people will be ...

Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the ...

Dose-finding clinical trial in China designed to evaluate safetyand preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in ...

Title: Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug in combination with atezolizumab and bevacizumab in patients with unresectable, ...